Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.56 |
| ▸ | NPY1R | P25929 | 9/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.56 |
| ▸ | NPY2R | P49146 | 5/20 | 0.56 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335016 | 0.94 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2RENPEP | |
| SCHEMBL29869065 | 0.93 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL29407334 | 0.93 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL30474555 | 0.93 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL29429181 | 0.90 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30411494 | 0.90 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29374790 | 0.90 | NPY4R (0.58) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL31458901 | 0.90 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL30668288 | 0.89 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2RENPEP | |
| SCHEMBL29374559 | 0.89 | PTGS1 (0.43) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120053651-A | Application of one-carbon metabolism inhibitor in preparation of medicine for treating toxic diffuse goiter | 上海市第一人民医院 | 2025-05-30 | — | — | CN | disclosed |
| CN-119923278-A | Dendrimer compositions for targeted delivery of fantasy therapeutic agents | 约翰霍普金斯大学 | 2025-05-02 | — | — | CN | disclosed |
| US-20250114484-A1 | ULTRASMALL NANOPARTICLES AND METHODS OF MAKING AND USING SAME | UNIV CORNELL (US) | 2025-04-10 | — | — | US | disclosed |
| CN-119789874-A | Cannabis for targeted delivery vegetable dendrimer composition | 约翰霍普金斯大学 | 2025-04-08 | — | — | CN | disclosed |
| US-12228553-B2 | Ultrasmall nanoparticles and methods of making, using and analyzing same | CORNELL UNIVERSITY (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250009894-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME | Ashvattha Therapeutics, Inc. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12161734-B2 | Multimodal silica-based nanoparticles | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2024-12-10 | — | — | US | disclosed |
| CN-118903483-A | Nuclide internal irradiation treatment sensitization medicine and preparation method thereof | 华中科技大学同济医学院附属协和医院 | 2024-11-08 | — | — | CN | disclosed |
| US-12115231-B2 | Ultrasmall nanoparticles and methods of making and using same | CORNELL UNIVERSITY (US) | 2024-10-15 | — | — | US | disclosed |
| CN-107835696-B | Subminiature nanoparticles and methods of making and using the same | 康奈尔大学 | 2024-06-04 | — | — | CN | disclosed |
| CN-116410465-A | Acid-responsive block copolymer, responsive micelle, preparation method and application thereof | 国家纳米科学中心 | 2023-07-11 | — | — | CN | disclosed |
| US-20230140770-A1 | ULTRASMALL NANOPARTICLES AND METHODS OF MAKING AND USING SAME | CORNELL UNIVERSITY | 2023-05-04 | — | — | US | disclosed |
| CN-115350285-A | Selective delivery of dendrimers to brain tumors | 约翰霍普金斯大学 | 2022-11-18 | — | — | CN | disclosed |
| CN-114948935-A | Gallic acid derivative nano-drug, preparation method and application | 厦门大学 | 2022-08-30 | — | — | CN | disclosed |
| US-11419955-B2 | Multimodal silica-based nanoparticles | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2022-08-23 | — | — | US | disclosed |
| EP-2968621-B1 | MULTIMODAL SILICA-BASED NANOPARTICLES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114652843-A | Medicine for treating eye neovascularization, preparation method and application | 厦门大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-114392360-A | Dendrimer compositions and use in the treatment of neurological and CNS disorders | 约翰霍普金斯大学 | 2022-04-26 | — | — | CN | disclosed |
| US-11291737-B2 | Ultrasmall nanoparticles and methods of making and using same | CORNELL UNIVERSITY (US) | 2022-04-05 | — | — | US | disclosed |
| CN-112773777-B | cRGD-DFX-BSA-NPS nano particle and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009894-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME | TLR9, TLR3, ALB | NPY4R 4650/4885NPY1R 4537/4885NPY5R 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.